Vaccine-Preventable Diseases
31
5
8
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 31 trials
100.0%
+13.5% vs benchmark
19%
6 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (31)
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
Game-Based Intervention to Promote HPV Vaccination
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
Playing Game to Learn About Children's Vaccine Project
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
Herpes Virus Infections in Kidney Transplant Patients
Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above